MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Up 38.9% in March

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 980,100 shares, a growth of 38.9% from the February 28th total of 705,700 shares. Currently, 8.0% of the shares of the stock are sold short. Based on an average daily volume of 352,300 shares, the days-to-cover ratio is currently 2.8 days.

Hedge Funds Weigh In On MIRA Pharmaceuticals

Large investors have recently modified their holdings of the company. Two Sigma Investments LP purchased a new stake in MIRA Pharmaceuticals in the fourth quarter worth approximately $28,000. International Assets Investment Management LLC bought a new position in shares of MIRA Pharmaceuticals during the 4th quarter valued at $29,000. Northern Trust Corp raised its position in MIRA Pharmaceuticals by 50.9% in the 4th quarter. Northern Trust Corp now owns 30,362 shares of the company’s stock worth $35,000 after purchasing an additional 10,238 shares during the period. Renaissance Technologies LLC bought a new stake in MIRA Pharmaceuticals in the fourth quarter worth $52,000. Finally, Virtu Financial LLC bought a new position in shares of MIRA Pharmaceuticals during the fourth quarter valued at about $72,000. 35.16% of the stock is owned by hedge funds and other institutional investors.

MIRA Pharmaceuticals Price Performance

Shares of MIRA opened at $1.06 on Monday. MIRA Pharmaceuticals has a 1-year low of $0.51 and a 1-year high of $5.01. The company has a market capitalization of $17.55 million, a P/E ratio of -1.89 and a beta of 2.31. The firm’s 50 day simple moving average is $1.12 and its 200 day simple moving average is $1.22.

MIRA Pharmaceuticals (NASDAQ:MIRA) last issued its quarterly earnings results on Friday, March 28th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.14. On average, equities analysts anticipate that MIRA Pharmaceuticals will post -0.6 earnings per share for the current year.

About MIRA Pharmaceuticals

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.